Class summary at a glance.

Every drug in the Thalidomide Analog class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $13.44Bcombined across class
Total Rx claims: 815K151K unique beneficiaries
Generic mfrs (active): 23across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Lenalidomide

Brand: Revlimid · 666K Part D claims (CY24) · 125K beneficiaries · First FDA approval: 2005-12-27

18 generic mfrs 2046 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $10.15B

Class share

76%

of class CY24 spend

View profile →

Pomalidomide

Brand: Pomalyst · 149K Part D claims (CY24) · 26K beneficiaries · First FDA approval: 2013-02-18

5 generic mfrs 1308 plans require PA